3/7
12:26 pm
cgem
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $35.00 price target on the stock, down previously from $38.00.
Low
Report
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $35.00 price target on the stock, down previously from $38.00.
3/7
12:26 pm
cgem
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $35.00 price target on the stock, down previously from $38.00.
Low
Report
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) had its "overweight" rating re-affirmed by analysts at Morgan Stanley. They now have a $35.00 price target on the stock, down previously from $38.00.
3/7
12:20 pm
cgem
Rating for CGEM
Low
Report
Rating for CGEM
3/7
12:20 pm
cgem
Rating for CGEM
Low
Report
Rating for CGEM
2/28
08:13 am
cgem
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $33.00 price target on the stock.
High
Report
Cullinan Therapeutics, Inc. (NASDAQ: CGEM) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $33.00 price target on the stock.